PAR paradigm biopharmaceuticals limited..

Ann: Loyalty and Piggyback Options Program, page-555

  1. 40 Posts.
    lightbulb Created with Sketch. 7
    Personally I don’t think the goal posts have moved to requiring peer review to progress funding. Those commercial entities in discussions / data room access will be doing their own equivalent peer review and due diligence of the data.

    So I think nothing has changed in terms of current funding options and the company is working towards binding agreements to fund phase 3 as per direction provided at the AGM.

    However, if language / on record commentary from C suite does pivot towards requiring peer review to finalise funding for phase three, I think that would tell all us battlers everything we need to know.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
43.0¢
Change
0.000(0.00%)
Mkt cap ! $170.8M
Open High Low Value Volume
43.0¢ 43.0¢ 41.5¢ $141.6K 337.6K

Buyers (Bids)

No. Vol. Price($)
1 9738 41.5¢
 

Sellers (Offers)

Price($) Vol. No.
43.0¢ 76716 4
View Market Depth
Last trade - 16.10pm 25/07/2025 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.